Approved in October 2006
Chronic Obstructive Pulmonary Disease
Brovana is a selective beta2-adrenergic bronchodilator. Beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle. They cause stimulation of intracellular adenyl cyclase which in turn causes relaxation of bronchial smooth muscle.
Brovana is specifically indicated for the long term, twice daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Brovana is supplied as 2 mL of a sterile solution in unit-dose, low-density polyethylene vials individually overwrapped in foil. It is designed for use as an inhalation solution. The recommended initial dose of the drug is 15 mcg administered twice a day (morning and evening) by nebulization.
FDA approval of Brovana was based on the results of two clinical trials. These were identical, 12-week, double-blind, placebo- and active-controlled, randomized, multi-center, parallel group trials. A total of 1,456 subjects were enrolled. Subjects received 15 or 25 mcg of Brovana twice daily, 50 mcg of Brovana once daily or placebo. Both trials included salmeterol inhalation aerosol, 42 mcg twice daily as an active comparator. In both trials Brovana administered at 15 mcg twice daily resulted in significantly greater post-dose bronchodilation (as measured by percent change from study baseline FEV1 at the end of the dosing interval over the 12 weeks of treatment) compared to placebo. At the 25 and 50 mcg doses, Brovana did not demonstrate sufficient enough benefit on a number of endpoints to support the use of higher doses. In addition, when compared to placebo, the subjects treated with Brovana demonstrated improvements in peak expiratory flow rates, supplemental ipratropium and rescue albuterol use.
Ongoing Study Commitments
Adverse events associated with the use of Brovana may include, but are not limited to, the following:
In addition, Brovana has been seen to cause infrequent yet clinically significant changes in systolic and/or diastolic blood pressure, pulse rate and electrocardiograms. Treatment should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders or thyrotoxicosis; and in patients who are unusually responsive to sympathomimetic amines. Beta-agonist medications may also produce significant hypokalemia in some patients. Brovana is contraindicated in patients with a history of hypersensitivity to arformoterol, racemic formoterol or to any other components of this product.
Brovana is a selective beta2-adrenergic bronchodilator. Beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle. They cause stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased intracellular cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
For additional information regarding Brovana or chronic obstructive pulmonary disease, please visit the Brovana web page.
The Brovana (arformoterol tartrate) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.